When a generic drug is easy to make, everyone makes it. Margins collapse, differentiation disappears, and the manufacturer becomes a commodity supplier. Strides Pharma Science, founded in Bangalore in 1990, built its business on the opposite premise: focus on formulations that are difficult to manufacture — soft gels, controlled substances, sterile injectables, suspensions — where the barriers to entry are high enough to sustain margins across 100 countries.
Strides’ defining strategic choice is its focus on dosage forms that competitors avoid. Soft gelatin capsules require specialised encapsulation equipment and humidity-controlled environments. Controlled substances demand DEA-registered facilities and meticulous inventory tracking. Sterile injectables need cleanroom manufacturing and validated aseptic processes. Oral suspensions and solutions involve different stability profiles than solid dosage forms.
Each of these categories carries higher capital requirements and regulatory complexity than standard tablets and capsules. But that is precisely the point. In markets where a simple generic tablet might face twenty competitors, a controlled-substance soft gel might face two or three. Strides has spent three decades building the manufacturing infrastructure, regulatory approvals, and quality systems to operate in these less-contested spaces.
The strategy delivered best-ever financial performance in FY 2024 and FY 2025, with revenue reaching $547 million and 17.2% year-over-year growth. The growth came not from a single product or market but from the steady accumulation of complex formulation approvals across regulated and emerging markets.
Strides’ corporate history includes a transformative merger and a subsequent strategic unbundling. In FY 2016, Strides Arcolab merged with Shasun Pharmaceuticals to form Strides Shasun, creating a vertically integrated company with both API and finished-dosage capabilities. Revenue more than doubled to $381 million, then peaked at $524 million in FY 2017 with 5,800 employees.
But vertical integration proved to be a distraction from the core thesis. In FY 2018, the company demerged its API and specialty chemicals business, rebranding as Strides Pharma Science and refocusing exclusively on niche finished-dosage formulations. Revenue dropped to $343 million and the workforce halved — a deliberate contraction that traded scale for focus.
The bet has paid off. From that post-demerger base, Strides rebuilt to $547 million in FY 2025, growing through its core capability in difficult-to-manufacture products rather than through vertical integration or diversification. The company that tried to do everything found its best results by doing one thing exceptionally well.
Strides operates across both regulated markets (the US, EU, Australia, Canada) and emerging markets (Africa, South-East Asia, Latin America), with a product portfolio tailored to each. In regulated markets, the company focuses on complex generic formulations — controlled substances, soft gels, and sterile products — where regulatory approval timelines are longer but competitive intensity is lower. In emerging markets, it leverages its institutional business, supplying antiretrovirals and antimalarials to government health programmes and international agencies.
This dual-market strategy provides revenue diversification that purely US-focused generics companies lack. When US pricing pressure intensifies, the emerging-market institutional business provides counter-cyclical stability. When tender volumes fluctuate in emerging markets, regulated-market product launches fill the gap.
Sources: Strides Pharma Annual Reports FY2014–15 through FY2024–25. US FDA facility registration data.